⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 15, 2025

Supplemental Table 5 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for MTAP-Deleted Cancer

Nikola Knoll Sarah Masser Blanka Bordas Richard Y. Ebright Guangyan Li Devishi Kesar Eliana Destefanis Nicholas Kania Diego J. Rodriguez Jayu Jen Sydney E. Zagar Caleb Mensah Zixin Chen Samuel J. Moffitt Erhumuoghene M. Enakireru Yao He Baomou Feng Mira K. Chokshi Cyrus Y. Jin Srivatsan Raghavan William R. Sellers Kathleen M. Mulvaney

View at Publisher

Ask AI

Bookmark

Share

Key Points

Identifying effective treatments highlights potential for targeted therapies in MTAP-deleted cancer, improving outcomes.
PRMT5 and ERK substrates identified in the screening indicate important molecular targets for combination therapy.
The combinatorial screening technique demonstrates a promising approach to discover innovative cancer treatments.
These findings may pave the way for personalized medicine strategies in cancers featuring MTAP deletions.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Supplemental table reveals PRMT5 and ERK methyl and phospho substrates in MTAP-deleted cancer, suggesting new therapies.

Abstract

Table S5. PRMT5 methyl substrates; ERK phospho substrates

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Knoll et al. (2025) studied this question.

synapsesocial.com/papers/68d4538731b076d99fa5895b https://doi.org/10.1158/0008-5472.30125703

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S8 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for <i>MTAP</i>-Deleted Cancer2025
2Figure S18 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for <i>MTAP</i>-Deleted Cancer2025
3Figure S16 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for <i>MTAP</i>-Deleted Cancer2025
4Figure S12 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for <i>MTAP</i>-Deleted Cancer2025
5Figure S7 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for <i>MTAP</i>-Deleted Cancer2025

Figure S6 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for <i>MTAP</i>-Deleted Cancer2025
Figure S17 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for <i>MTAP</i>-Deleted Cancer2025
Figure S1 from CRISPR–Drug Combinatorial Screening Identifies Effective Combination Treatments for <i>MTAP</i>-Deleted Cancer2025